Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines

[1]  Sita J. Saunders,et al.  Critical Review of European Health-Economic Guidelines for the Health Technology Assessment of Medical Devices , 2019, Front. Med..

[2]  Juan Manuel Ramos-Goñi,et al.  The EQ-5D-5L Valuation study in Thailand , 2018, Expert review of pharmacoeconomics & outcomes research.

[3]  Wenjuan Ma,et al.  A systematic review of pharmacoeconomic guidelines , 2018, Journal of medical economics.

[4]  Z. Kaló,et al.  HTA Implementation in Latin American Countries: Comparison of Current and Preferred Status. , 2017, Value in health regional issues.

[5]  D. Rowen,et al.  International Regulations and Recommendations for Utility Data for Health Technology Assessment , 2017, PharmacoEconomics.

[6]  N. Devlin,et al.  EQ-5D and the EuroQol Group: Past, Present and Future , 2017, Applied Health Economics and Health Policy.

[7]  Dominik Golicki,et al.  EQ-5D in Central and Eastern Europe: 2000–2015 , 2016, Quality of Life Research.

[8]  M. Huic,et al.  HTA Implementation Roadmap in Central and Eastern European Countries , 2016, Health economics.

[9]  J. Richardson,et al.  Why do multi-attribute utility instruments produce different utilities: the relative importance of the descriptive systems, scale and ‘micro-utility’ effects , 2015, Quality of Life Research.

[10]  Guenka Petrova,et al.  Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria , 2014, The European Journal of Health Economics.

[11]  S. Jang,et al.  Korean Guidelines for Pharmacoeconomic Evaluation (Second and Updated Version) , 2013, PharmacoEconomics.

[12]  J. Richardson,et al.  Multiattribute Utility Instruments and Their Use , 2014 .

[13]  I. Kamae.  Value-Based Approaches to Healthcare Systems and Pharmacoeconomics Requirements in Asia , 2012, PharmacoEconomics.

[14]  Bong-min Yang.  The Future of Health Technology Assessment in Healthcare Decision Making in Asia , 2012, PharmacoEconomics.